P3160 - Outcomes After Major Adverse Cardiovascular Events in MASLD Patients: A Nationwide Inpatient Sample Study

Prince A. Ameyaw, MD¹, Sarpong Boateng, MD, MPH¹, Amoafo Boampong, MD², Derek Ugwendum, MD, MPH³, Tawanda Zinyandu, MD, MPH¹, Isaac Adjei Opoku, MD¹, Ashraf Ahmed, MD¹, Basile Njei, MD^4
1Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT; ²Howard University Hospital, Washington, DC; ³Richmond University Medical Center, Staten Island, NY; ⁴Yale University School of Medicine, New Haven, CT

Introduction: Metabolic Dysfunction-Associated Steatohepatitis Liver Disease (MASLD) is a growing public health concern due to its association with obesity and increased risk of cardiovascular events. This study investigates the outcomes after major adverse cardiovascular events (MACEs) in patients with MASLD, focusing on differences between obese and non-obese MASLD patients using data from the National Inpatient Sample (NIS).

Methods: We conducted a retrospective analysis using the NIS database from 2016 to 2020, identifying patients diagnosed with MASLD who experienced MACEs. MACEs were defined as a composite of acute myocardial infarction, cardiac arrest, stroke, heart failure, and atrial fibrillation. Patient characteristics, comorbidities, and outcomes were compared between obese and non-obese MASLD patients. After adjusting for age, sex, race, smoking, cardiometabolic risk factors, hospital characteristics, socio-economic factors, prior myocardial infarction and comorbidities, multivariable logistic and Poisson regression models were used to assess the association between obesity and outcomes after MACEs in MASLD patients

Results: The study included 106,546 patients with MASLD who experienced MACEs, of which 41.9% were classified as obese. Patients with obese MASLD were younger (mean age 62.1 vs. 67.2 years, p< 0.0001) compared to non-obese MASLD patients.

Outcomes showed significant differences between the two groups. For obese MASLD patients, the adjusted odds ratio for acute kidney injury was higher (aOR: 1.080, 95% CI: 1.048–1.112, p< 0.0001) compared to non-obese MASLD patients. Obese MASLD patients also had higher adjusted odds of in-hospital death (aOR: 1.21, 95% CI: 1.14–1.28, p< 0.0001) compared to non-obese MASLD patients. Additionally, obese MASLD patients incurred higher inflation-adjusted hospital charges ($2,262.57, 95% CI: $509.27–$4,015.87, p=0.0114) and longer adjusted length of stay (aOR: 0.360, 95% CI: 0.257–0.464, p< 0.0001).

Discussion: Obesity in MASLD patients significantly influences outcomes after MACEs: obese MASLD patients are more likely to develop acute kidney injury and have higher in-hospital mortality, hospital charges, and length of stay. These findings highlight the need for tailored management strategies for obese MASLD patients to improve cardiovascular outcomes. Further research is warranted to understand the underlying mechanisms and to develop effective interventions.



Disclosures:


Prince A. Ameyaw, MD¹, Sarpong Boateng, MD, MPH¹, Amoafo Boampong, MD², Derek Ugwendum, MD, MPH³, Tawanda Zinyandu, MD, MPH¹, Isaac Adjei Opoku, MD¹, Ashraf Ahmed, MD¹, Basile Njei, MD⁴. P3160 - Outcomes After Major Adverse Cardiovascular Events in MASLD Patients: A Nationwide Inpatient Sample Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.